Relay Therapeutics (RLAY) Liabilities and Shareholders Equity (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $699.6 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $699.6 million, down 12.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 billion (down 19.37% YoY), and the FY2025 annual result was $621.3 million, down 28.69% from the prior year.
• Liabilities and Shareholders Equity improved to $699.6 million in Q1 2026 per RLAY's latest filing, from $621.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.2 billion in Q3 2022 and troughed at $621.3 million in Q4 2025.
• A 5-year average of $870.2 million and a median of $871.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 74.02% in 2022, then slipped 28.69% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.1 billion in 2022, then decreased by 23.26% to $844.0 million in 2023, then climbed by 3.24% to $871.3 million in 2024, then fell by 28.69% to $621.3 million in 2025, then climbed by 12.6% to $699.6 million in 2026.
• Business Quant data shows RLAY's Liabilities and Shareholders Equity at $699.6 million in Q1 2026, $621.3 million in Q4 2025, and $670.0 million in Q3 2025.